logo

Centre of Evidence of Dermatology Best practice guidelines

Guidelines hidradenitis suppurativa Updated on august 2019

Responsibility


The information provided by this website comes from sources deemed reliable. However, the French Dermatology Society recommends that the user ensure the validity of this information. Some may prove to be erroneous or be subject to typos or display errors.

The use of this data is under the sole responsibility of the user. The French Dermatology Society cannot be blamed for a misinterpretation of the data provided by the site, or in the event of erroneous information. This decision tree and all the contents of this site have been developed in the context of updated data from science according to the HAS methodology, expert opinions and reviewers of the various documents and in the context of the French healthcare system.


Anti-TNF treatments

Back to decision-making tree Print last updated on 10/11/2020

Anti-TNFα: Adalimumab

The PIONEER Ⅰ and Ⅱ trials lead to the granting of a European MA in 2015 with the indication: “Humira® is indicated for the treatment of active moderate to severe hidradenitis suppurative (Verneuil disease), in adults with an inadequate response to conventional systemic HS therapy”.

In 2016, the Transparency Committee of the French Haute Autorité de Santé (HAS) (in charge of the drug-reimbursement policy) determined that the therapeutic value of adalimumab was insufficient to justify its reimbursement from public solidarity funds for the above-mentioned treatment, considering:

Adalimumab, considering the data in the literature, does not appear to be a viable candidate for long-term treatment in HS patients (loss of efficacy). A dialogue with the patient should be engaged on therapeutic possibilities when introducing this biomedicine.

For patients presenting an associated disease such as inflammatory rheumatism or a chronic bowel inflammation disease, adalimumab may be considered at an earlier stage of treatment.

Where no other therapeutic alternatives exist, and despite its limited efficacy, this treatment may be considered in patients presenting HS with Hurley stage Ⅱ and Ⅲ lesions as a backup to large-spectrum antibiotherapy (as described above). This treatment should be reviewed regularly, and should be interrupted if the expected efficacy is not observed in 3 to 6 months

Under the current health regulations regarding anti-TNFα medicines in the treatment of HS, the delivery of adalimumab on prescription cannot be reimbursed, although it may be declared reimbursable after amicable negotiation with the local social security establishment.

Anti-TNFα: Infliximab

HS is not indicated in the MA for infliximab. The work group nevertheless recommends its use by analogy with adalimumab, which is not covered by social security reimbursement. This medicine should be restricted for use only by teams specialised in the treatment of patients with severe HS, or forms resistant to first-line treatment. Its indication should be re-evaluated after 3 to 6 months.

  • Was this article helpful to you?
  • Your opinion counts!

    This notice will not be published on this site, but only sent to the publication management. Your email will only be used to reply to you if we deem it necessary. No response will be sent to any request for medical advice via this form.


read retinoids

Centre of Evidence of Dermatology Centre of Evidence of Dermatology logo
Work
10 cité Malesherbes
75009Paris
Île-de-France
FRANCE
Work +33.1 43 27 01 56
Fax +33.1 43 27 01 86
centredepreuvesdermato@sfdermato.org